Biosplice therapeutics crunchbase
WebAACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics October 07 - 10, 2024 Safety, Tolerability, and Pharmacokinetics of an Intra-articular Corticosteroid Injection Administered 7 Days Before or After Intra-articular Lorecivivint Injection into the Same Knee of Healthy Volunteers: An Open-Label ... WebWhat We Do. Biosplice Therapeutics has produced fresh biological insights and unique chemical equity that delivers therapeutic modulation of alternative splicing by targeting the CLK/DYRK family kinases. These …
Biosplice therapeutics crunchbase
Did you know?
WebJun 18, 2024 · Biosplice Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT04931667 Other Study ID Numbers: SM04690-OA-17 : First Posted: June 18, 2024 Key Record Dates: Last Update Posted: January 10, 2024 Last Verified: December 2024 Individual Participant Data (IPD) Sharing Statement: ... Web22 rows · Pipeline. Biosplice Therapeutics has designed an unprecedented compendium of new chemical entities which selectively bind to specific members of the CLK/DYRK family and feature drug-like …
WebSep 29, 2024 · 11/17/2024. Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, announced the dosing of the first subject in a Phase 1b, open-label, multi-center, dose-escalation, dose expansion clinical trial of cirtuvivint in subjects with ... WebJan 27, 2024 · Jan 27, 2024, 13:00 ET. SAN DIEGO, Jan. 27, 2024 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering …
WebAfter reaching a $12 billion valuation in 2024, Biosplice appears to be falling back down to Earth, and its workforce is taking the brunt. After reaching a $12 billion valuation in 2024 ... WebSep 29, 2024 · add_box. SAN DIEGO, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase ...
WebApr 22, 2024 · PRESS RELEASE Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Samil for the Republic of Korea SAN DIEGO – April 22, 2024 – Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for
WebNov 15, 2024 · Biosplice Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT03742518 Other Study ID Numbers: SM04554-AGA-05 : First Posted: November 15, 2024 Key Record Dates: Last Update Posted: December 28, 2024 Last Verified: December 2024 iphone 2wWebDec 15, 2024 · Biosplice Therapeutics, Inc. Unique interim X-ray results from an ongoing long-term extension study suggest structure-modifying benefit of repeat injections of lorecivivint, as measured by medial ... iphone 2 vs 3WebNov 11, 2024 · SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule ... iphone 2 way radio appWebJul 9, 2024 · As more investment pours into startups with lifespan-increasing goals, we turned to the Crunchbase database to put together some targeted lists of companies and categories gaining traction. To narrow … iphone 2 vs iphone 6WebApr 15, 2024 · Sep 15. Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco for the People’s Republic of China. Sep 15. FierceBiotech: Haisco to Pay $140M to Get the Ball rolling on Biosplice's Phase 3 Osteoarthritis Drug in China. Jul 22. iphone 2 vs iphone 3WebApr 22, 2024 · SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing ... iphone 2 year warrantyiphone 30 pin extension